- Home
- OGEN vs ROMA Comparison
OGEN vs ROMA Comparison
Compare OGEN & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- ROMA
- Stock Information
- Founded
- OGEN 1996
- ROMA 2018
- Country
- OGEN United States
- ROMA Hong Kong
- Employees
- OGEN N/A
- ROMA N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- ROMA Savings Institutions
- Sector
- OGEN Health Care
- ROMA Finance
- Exchange
- OGEN Nasdaq
- ROMA Nasdaq
- Market Cap
- OGEN 5.4M
- ROMA 158.1M
- IPO Year
- OGEN N/A
- ROMA 2024
- Fundamental
- Price
- OGEN $0.88
- ROMA $2.61
- Analyst Decision
- OGEN
- ROMA
- Analyst Count
- OGEN 0
- ROMA 0
- Target Price
- OGEN N/A
- ROMA N/A
- AVG Volume (30 Days)
- OGEN 49.3K
- ROMA 12.1K
- Earning Date
- OGEN 11-07-2025
- ROMA 12-15-2025
- Dividend Yield
- OGEN N/A
- ROMA N/A
- EPS Growth
- OGEN N/A
- ROMA N/A
- EPS
- OGEN N/A
- ROMA N/A
- Revenue
- OGEN N/A
- ROMA $1,568,345.00
- Revenue This Year
- OGEN N/A
- ROMA N/A
- Revenue Next Year
- OGEN N/A
- ROMA N/A
- P/E Ratio
- OGEN N/A
- ROMA N/A
- Revenue Growth
- OGEN N/A
- ROMA 23.21
- 52 Week Low
- OGEN $0.82
- ROMA $0.58
- 52 Week High
- OGEN $18.90
- ROMA $4.66
- Technical
- Relative Strength Index (RSI)
- OGEN 23.69
- ROMA 43.27
- Support Level
- OGEN $1.06
- ROMA $2.53
- Resistance Level
- OGEN $1.22
- ROMA $2.75
- Average True Range (ATR)
- OGEN 0.08
- ROMA 0.10
- MACD
- OGEN -0.02
- ROMA -0.02
- Stochastic Oscillator
- OGEN 18.82
- ROMA 19.84
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.